Table 3.
TP53 and PIK3CA mutations in primary breast cancer tumors and brain metastases with NGS results fulfilling sequencing quality criteria.
| All (n = 57) | Luminal B-like (n = 14) | TNBC (n = 26) | HER2 + (n = 17) | |
|---|---|---|---|---|
| Mean (SD) brain metastasis specific survival (months) | 17 (16.9) | 28 (18.9) | 9 (7.4) | 21 (19.8) |
| Median (min; max) brain metastasis specific survival (months) | 12.5 (0; 64) | 28 (6; 64) | 8 (1; 25) | 13 (0; 62) |
| Mean (SD) overall survival (months) | 69 (52.3) | 98 (41) | 57 (60.7) | 66 (33.4) |
| Median (min; max) overall survival (months) | 50 (10; 288) | 91 (35; 177) | 40 (10; 288) | 96 (42; 107) |
The bottom row shows the concordance in mutation status in the 37 matched brain metastasis and primary breast tumors.